Skip to main content
Clinical Trials/CTRI/2024/10/075616
CTRI/2024/10/075616CompletedNot Applicable

Assessment and evaluation of anxiety and depression on quality of life among chronic kidney disease patients in the nephrology ward of a tertiary care hospital: A cross-sectional study.

KLEs DrPRABHAKAR KORE HOSPITAL AND MRC BELAGAVI1 site in 1 country106 target enrollmentStarted: October 29, 2024Last updated:

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
106
Locations
1
Primary Endpoint
To assess the prevalence of anxiety and depression in chronic kidney disease (CKD) patients using the appropriate scales.

Study Overview

Brief Summary

This cross-sectional study focuses on assessing the prevalence and severity of anxiety and depression in chronic kidney disease (CKD) patients and their effect on the patients’ quality of life. Using the PHQ-9 and GAD-7 scales to measure anxiety and depression, along with the WHOQOL-BREF to assess quality of life, the study aims to understand how mental health issues impact CKD patients. It also seeks to explore the influence of sociodemographic factors on these conditions, ultimately aiming to improve clinical care and treatment strategies by addressing the often-overlooked mental health challenges in CKD patients within a tertiary care hospital setting.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
18.00 Year(s) to 80.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • The study included patients over the age of 18 who had a confirmed diagnosis of Chronic Kidney Disease (CKD),able to read and understand the language of the assessment tools used, and willing to provide informed consent and complete all study procedures.

Exclusion Criteria

  • Patients were excluded if they had incomplete demographic or laboratory data, had conditions other than Chronic Kidney Disease (CKD), were unwilling to provide necessary information, were experiencing an acute psychiatric crisis requiring immediate intervention, had a terminal illness with limited life expectancy, were unable to participate due to severe physical limitations, or were over the age of 80.

Outcomes

Primary Outcomes

To assess the prevalence of anxiety and depression in chronic kidney disease (CKD) patients using the appropriate scales.

Time Frame: 6 MONTHS

Secondary Outcomes

  • TO ASSESS THE CO-RELATION OF ANXIETY AND DEPRESSION WITH QOL IN CKD PATIENTS.(6 MONTHS)
  • TO ASSESS THE EFFECTS OF VARIOUS SOCIO-DEMOGRAPHIC AND DISEASE FACTORS OF ANXIETY AND DEPRESSION ON QOL IN CKD PATIENTS.(6 MONTHS)

Investigators

Sponsor
KLEs DrPRABHAKAR KORE HOSPITAL AND MRC BELAGAVI
Sponsor Class
Research institution and hospital
Responsible Party
Principal Investigator
Principal Investigator

HARSHAVARDHAN

KLE COLLEGE OF PHARMACY BELAGAVI

Study Sites (1)

Loading locations...

Similar Trials